Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy

Practical Radiation Oncology

Volumn 3, Issue 3, 2013, Pages 216-222

  Filippi, Andrea Riccardo ^a   Ragona, Riccardo ^a   Fusella, Marco ^a   Botticella, Angela ^a   Fiandra, Christian ^a   Ricardi, Umberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOSIMETRY; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; INVOLVED FIELD RADIATION THERAPY; INVOLVED NODAL RADIATION THERAPY; ORGAN EQUIVALENT DOSE; ORGAN SIZE; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT; RISK REDUCTION; SUPRADIAPHRAGMATIC RADIATION THERAPY; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; VOLUMETRIC MODULATED ARC THERAPY;

EID: 84879883656     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2012.12.006     Document Type: Article

References (24)

1. Van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18:487-497.
2. Ng A.K., Bernardo M.V., Weller E., et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989-1996.
3. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 2002, 20:3484-3494.
4. Travis L.B., Hill D., Dores G.M., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428-1437.
5. Hill D.A., Gilbert E., Dores G.M., et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: Modification by other risk factors. Blood 2005, 106:3358-3365.
6. Van Leeuwen F.E., Klokman W.J., Stovall M., et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
7. De Bruin M.L., Sparidans J., van't Veer M.B., et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol 2009, 27:4239-4246.
8. Girinsky T., Van Der Maazen R., Specht L., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270-277.
9. Weber D.C., Peguret N., Dipasquale G., Cozzi L. Involved-node and Involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009, 75:1578-1586.
10. Nieder C., Schill S., Kneschaurek P., Molls M. Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol 2007, 82:301-307.
11. Campbell B.A., Hornby C., Cunningham J., et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 2012, 23:1259-1266.
12. Weber D.C., Johanson S., Peguret N., Cozzi L., Olsen D.R. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81:490-497.
13. Yahalom J., Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002, 13(Suppl. 1):79-83.
14. Alber M., Nüsslin F. An objective function for radiation treatment optimization based on local biological measures. Phys Med Biol 1999, 44:479-493.
15. Fiandra C., Filippi A.R., Catuzzo P., et al. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7:186.
16. Zwahlen D.R., Martin J.M., Millar Jl, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008, 70:853-858.
17. Daşu A., Toma-Daşu I., Olofsson J., Karlsson M. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncol 2005, 44:339-347.
18. Sachs R.K., Brenner D.J. Solid tumors after high doses of ionizing radiation. Proc Natl Acad Sci U S A 2005, 102:13040-13045.
19. Schneider U., Walsh L. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys 2008, 47:253-263.
20. Schneider U., Sumila M., Robotka J., Gruber G., Mack A., Besserer J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol 2011, 6:67.
21. Koh E.S., Tran T.H., Heydarian M., et al. A comparison of mantle versus involved field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2:13.
22. Hall E.J., Wuu C.S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003, 56:83-88.
23. Ruben J.D., Davis S., Evans C., et al. The effect of intensity modulated radiation therapy on radiation-induced second malignancies. Int J Radiat Oncol Biol Phys 2008, 70:1530-1536.
24. Hoppe BS, Flampouri S, Lynch J, et al. Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology (Williston Park). 2012;26:456-459, 462-465.